Evidence map›Paper›PMID 36660692›Full record

ArticleAnnals of translational medicine2022

Mucin 1 downregulation decreases the anti-tumor effects of melanoma vaccine.

Fangfang Shi, Rui Xue, Hui Xu, Feng Mei, Xueyang Bao, Jun Dou, Fengshu Zhao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fangfang ShiDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Rui XueDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Hui XuDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Feng MeiDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Xueyang BaoDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Jun DouDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Fengshu ZhaoDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.
Southeast University · CNZhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immunotherapy-based approaches are important breakthroughs with potential treatment benefits for melanoma patients. Mucin 1 (MUC1) is significantly upregulated in melanoma relative to normal cells. It has been reported that MUC1 influences cancer cell proliferation, apoptosis, invasion, and metastasis.The study aimed to explore the effect of Methods: First, lentiviral vector-mediated short hairpin RNA (shRNA) was used to knockdown Results: It was revealed that sh Conclusions: MUC1 has strong melanoma vaccine immunogenicity, and induces the host's anti-tumor reaction.

Indexed as

Melanomamelanoma vaccinemucin 1 (MUC1)target antigenvaccination

Identifiers

PMID36660692
PMCPMC9843407
OpenAlexW4313416346

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.